DCTH · Delcath Systems Inc. Common Stock
View on chartInsiders & Stakes
| Gil Aharon Director | ▼ Sell | Other | 3,413,468 Shares held | 5/5/2025 | View profile |
| Steven A. J. Salamon Director | ▼ Sell | Other | 3,413,468 Shares held | 5/5/2025 | View profile |
| Rosalind Advisors, Inc. Director | ▼ Sell | Other | 3,413,468 Shares held | 5/5/2025 | View profile |
| Gerard J. Michel See Remarks | ▲ Buy | Open Market | 342,034 Shares held | 3/2/2026 | View profile |
| Vojo Vukovic Chief Medical Officer | ▲ Buy | Option Exercise | 168,882 Shares held | 6/12/2025 | View profile |
| Sandra Pennell SVP of Finance, PFO and PAO | ▲ Buy | Open Market | 77,018 Shares held | 3/6/2026 | View profile |
| Hoffman David L. See Remarks | ▲ Buy | Grant | 74,330 Shares held | 3/19/2024 | View profile |
| Purpura John Chief Operating Officer | ▲ Buy | Open Market | 41,526 Shares held | 10/13/2023 | View profile |
| Muir Kevin GM INTERVENTIONAL ONCOLOGY | ▲ Buy | Grant | 18,582 Shares held | 3/19/2024 | View profile |
| John Richard Sylvester Director | ▲ Buy | Open Market | 14,936 Shares held | 11/21/2025 | View profile |
Transaction History
| Sandra Pennell | ▲ Buy | Open Market | 5,533 | $50K | 3/6/2026 |
| Gerard J. Michel | ▲ Buy | Open Market | 11,200 | $100K | 3/2/2026 |
| John Richard Sylvester | ▲ Buy | Open Market | 4,386 | $39K | 11/21/2025 |
| Gerard J. Michel | ▲ Buy | Open Market | 11,500 | $98K | 11/11/2025 |
| Vojo Vukovic | ▲ Buy | Option Exercise | 42,000 | $201K | 6/12/2025 |
| Gil Aharon | ▼ Sell | Other | 400,000 | $4.0M | 5/5/2025 |
| Rosalind Advisors, Inc. | ▼ Sell | Other | 400,000 | $4.0M | 5/5/2025 |
| Steven A. J. Salamon | ▼ Sell | Other | 400,000 | $4.0M | 5/5/2025 |
| Steven A. J. Salamon | ▼ Sell | Other | 250,000 | $2.5M | 12/24/2024 |
| Gil Aharon | ▼ Sell | Other | 250,000 | $2.5M | 12/24/2024 |
| Rosalind Advisors, Inc. | ▼ Sell | Other | 250,000 | $2.5M | 12/24/2024 |
| Gerard J. Michel | ▲ Buy | Option Exercise | 16,666 | $100K | 10/22/2024 |
| Gil Aharon | ▼ Sell | Other | 619,946 | $3843.3M | 4/18/2024 |
| Gil Aharon | ▼ Sell | Other | 991,615 | $0 | 4/18/2024 |
| Steven A. J. Salamon | ▼ Sell | Other | 991,615 | $0 | 4/18/2024 |
| Steven A. J. Salamon | ▼ Sell | Other | 619,946 | $3843.3M | 4/18/2024 |
| Rosalind Advisors, Inc. | ▼ Sell | Other | 619,946 | $3843.3M | 4/18/2024 |
| Rosalind Advisors, Inc. | ▼ Sell | Other | 991,615 | $0 | 4/18/2024 |
| Gil Aharon | ▲ Buy | Open Market | 26,882 | $100K | 3/19/2024 |
| Steven A. J. Salamon | ▲ Buy | Open Market | 26,882 | $100K | 3/19/2024 |
| Vojo Vukovic | ▲ Buy | Grant | 26,882 | $100K | 3/19/2024 |
| Gerard J. Michel | ▲ Buy | Grant | 40,323 | $150K | 3/19/2024 |
| Sandra Pennell | ▲ Buy | Grant | 26,881 | $100K | 3/19/2024 |
| Muir Kevin | ▲ Buy | Grant | 13,441 | $50K | 3/19/2024 |
| Hoffman David L. | ▲ Buy | Grant | 20,161 | $75K | 3/19/2024 |
| Vojo Vukovic | ▲ Buy | Open Market | 40,000 | $120K | 12/12/2023 |
| Gerard J. Michel | ▲ Buy | Open Market | 34,000 | $100K | 12/8/2023 |
| Rosalind Advisors, Inc. | ▲ Buy | Open Market | 100,000 | $240K | 11/17/2023 |
| Sandra Pennell | ▲ Buy | Open Market | 30,000 | $73K | 11/17/2023 |
| Vojo Vukovic | ▲ Buy | Open Market | 60,000 | $149K | 11/16/2023 |
| Hoffman David L. | ▲ Buy | Open Market | 40,000 | $99K | 11/16/2023 |
| Purpura John | ▲ Buy | Open Market | 14,505 | $50K | 10/13/2023 |
| John Richard Sylvester | ▲ Buy | Open Market | 10,550 | $51K | 8/21/2023 |
| Gerard J. Michel | ▼ Sell | Other | 31,110 | $140K | 8/18/2023 |
| Gerard J. Michel | ▲ Buy | Open Market | 19,646 | $95K | 3/29/2023 |
| Rosalind Advisors, Inc. | ▲ Buy | Open Market | 15,215 | $55K | 12/14/2022 |
| Steven A. J. Salamon | ▲ Buy | Open Market | 15,215 | $55K | 12/14/2022 |
| Gerard J. Michel | ▲ Buy | Open Market | 51,725 | $150K | 12/13/2022 |
| Gerard J. Michel | ▲ Buy | Open Market | 62,814 | $250K | 7/20/2022 |
| Purpura John | ▲ Buy | Open Market | 3,300 | $15K | 5/16/2022 |
| Steven A. J. Salamon | ▲ Buy | Open Market | 5,000 | $25K | 5/13/2022 |
| Steven A. J. Salamon | ▲ Buy | Open Market | 6,000 | $29K | 5/12/2022 |
| Rosalind Advisors, Inc. | ▲ Buy | Open Market | 1,600 | $10K | 4/19/2022 |
| Steven A. J. Salamon | ▲ Buy | Open Market | 1,600 | $10K | 4/19/2022 |
| Rosalind Advisors, Inc. | ▲ Buy | Open Market | 2,000 | $13K | 4/18/2022 |
| Gil Aharon | ▲ Buy | Open Market | 2,000 | $13K | 4/18/2022 |
| Gerard J. Michel | ▲ Buy | Open Market | 200 | $1K | 4/18/2022 |
| Gerard J. Michel | ▲ Buy | Open Market | 1,800 | $11K | 4/18/2022 |
| Rosalind Advisors, Inc. | ▲ Buy | Open Market | 1,500 | $10K | 4/13/2022 |
| Steven A. J. Salamon | ▲ Buy | Open Market | 1,500 | $10K | 4/13/2022 |
| Rosalind Advisors, Inc. | ▲ Buy | Open Market | 2,500 | $16K | 4/12/2022 |
| Steven A. J. Salamon | ▲ Buy | Open Market | 2,500 | $16K | 4/12/2022 |
| Purpura John | ▲ Buy | Open Market | 5,000 | $33K | 4/11/2022 |
| Gerard J. Michel | ▲ Buy | Open Market | 1,000 | $7K | 4/8/2022 |
| Gerard J. Michel | ▲ Buy | Open Market | 1,000 | $7K | 4/8/2022 |
| Steven A. J. Salamon | ▲ Buy | Open Market | 1,000 | $6K | 4/7/2022 |
| Rosalind Advisors, Inc. | ▲ Buy | Open Market | 1,000 | $6K | 4/7/2022 |
| Steven A. J. Salamon | ▲ Buy | Open Market | 1,000 | $6K | 4/6/2022 |
| Rosalind Advisors, Inc. | ▲ Buy | Open Market | 1,000 | $6K | 4/6/2022 |
| Steven A. J. Salamon | ▲ Buy | Open Market | 2,000 | $15K | 12/30/2021 |
| Rosalind Advisors, Inc. | ▲ Buy | Open Market | 2,000 | $15K | 12/30/2021 |
| Gerard J. Michel | ▲ Buy | Open Market | 23,200 | $200K | 12/2/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Veracyte stock moves; DCTH shows no related news
Recent news coverage focuses on Veracyte (VCYT) rather than Delcath Systems (DCTH). There are no specific reports or announcements regarding DCTH in the provided data. The stock currently trades with a high trailing P/E ratio, while analyst targets remain above the current price level.
Veracyte stock moves; DCTH shows no related news. Recent news coverage focuses on Veracyte (VCYT) rather than Delcath Systems (DCTH). There are no specific reports or announcements regarding DCTH in the provided data. The stock currently trades with a high trailing P/E ratio, while analyst targets remain above the current price level.